GLP-1 Agonist Liraglutide Reduces Vascular Calcification in Both Diabetic and Non-Diabetic Rats | Research

The takeaway

Liraglutide reduced vascular calcification in both diabetic and normoglycemic rat models, demonstrating a direct vascular protective effect independent of blood sugar control.

Works without diabetes
Liraglutide reduced vascular calcification even in non-diabetic rats, proving direct vascular protection beyond glucose control

What the researchers found

Liraglutide ameliorated vascular calcification in both normoglycemic and diabetic rat models, demonstrating direct vascular protection independent of glycemic control.

Why it matters

Vascular calcification has no treatment. Showing that liraglutide directly protects blood vessels — even without diabetes — suggests GLP-1 drugs could be used to treat or prevent vascular calcification in any patient.

The numbers in context

Young rats were 3–4 months old, compared to aged rats. Specific calcification measurements and pathway expression levels were analyzed but not fully detailed in the available abstract.

How the study worked

Vascular calcification models in both normoglycemic and diabetic rats. Treated with liraglutide. Assessed vascular calcium content, vessel function, and calcification markers.

Who was studied

Young (3–4 month) and aged rats without diabetes

What this study cannot tell us

Rat model. Human vascular calcification involves different pathologies (atherosclerotic vs medial). Optimal dosing for anti-calcification effect not established.

How to read the evidence

Preliminary evidence: dual-model rat study (diabetic + normoglycemic) demonstrating direct vascular protection. No human data.

When this study was published

Published in 2025. Significant finding for expanding GLP-1 drug indications beyond metabolic disease.

The bigger picture

Vascular calcification contributes to cardiovascular events in millions of people, including those with chronic kidney disease. Demonstrating that GLP-1 drugs work against calcification regardless of diabetes status dramatically expands their potential cardiovascular applications.

Questions still open

Could liraglutide prevent vascular calcification in chronic kidney disease patients?
What mechanism explains the direct anti-calcification effect independent of glucose control?
Should non-diabetic patients at high cardiovascular risk receive GLP-1 drugs for vascular protection?

Common questions

Can GLP-1 drugs protect blood vessels?

This study shows liraglutide directly reduced blood vessel calcification — even in rats without diabetes. This suggests GLP-1 drugs have vascular protective properties beyond their blood sugar effects, potentially benefiting anyone at risk for cardiovascular disease.

What is vascular calcification?

Vascular calcification is the buildup of calcium in blood vessel walls, making them stiff and less able to function. It is a major risk factor for heart attack and stroke, and currently has no approved drug treatment.

Read the original research

Ameliorative effect of GLP1 agonist on vascular calcification in normoglycemic aged rat aorta via miR34a/SIRT6/NRF2/HO-1 signalling pathway.

European journal of pharmacology, 1001, 177741

View on PubMed ↗Publisher’s paper ↗

Citation

Abdelfattah, Amira Mohammed; Abdelnour, Hanim M; Askar, Eman M; Abdelhamid, Amira Mohamed; Elgarhi, Reham I. (2025). Ameliorative effect of GLP1 agonist on vascular calcification in normoglycemic aged rat aorta via miR34a/SIRT6/NRF2/HO-1 signalling pathway.. European journal of pharmacology, 1001, 177741. https://doi.org/10.1016/j.ejphar.2025.177741